In November 2025, Kimberly-Clark announced it would buy Tylenol producer Kenvue for $48.7 billion. The deal would add the Aveeno, Band-Aid, Benadryl, Benylin, Calpol, Carefree, Clean & Clear, Combantrin, Imodium, Listerine, Motrin, Mylanta, Neutrogena, Nicorette, Johnson’s Baby, Sudafed, Visine, and Zyrtec brands to the company’s portfolio.
But also…
Kimberly-Clark shares are mainly held by institutional investors (The Vanguard Group, BlackRock, State Street Corporation, and others).
In November 2025, Kimberly-Clark announced it would buy Tylenol producer Kenvue for $48.7 billion. The deal would add the Aveeno, Band-Aid, Benadryl, Benylin, Calpol, Carefree, Clean & Clear, Combantrin, Imodium, Listerine, Motrin, Mylanta, Neutrogena, Nicorette, Johnson’s Baby, Sudafed, Visine, and Zyrtec brands to the company’s portfolio.[34][35]
Kimberly-Clark apparently.
But also…
So make of that what you will.
In November 2025, Kimberly-Clark announced it would buy Tylenol producer Kenvue for $48.7 billion. The deal would add the Aveeno, Band-Aid, Benadryl, Benylin, Calpol, Carefree, Clean & Clear, Combantrin, Imodium, Listerine, Motrin, Mylanta, Neutrogena, Nicorette, Johnson’s Baby, Sudafed, Visine, and Zyrtec brands to the company’s portfolio.[34][35]
Any time I see name BlackRock, ominous music starts playing out of nowhere.
Vanguard runs VOO and StateStreet runs SPY which are S&P500 ETF / Index Funds. That is why they have equity ownership in Kimberly-Clark.